These three abstracts from the 2020 virtual meeting of the American College of Gastroenterology are highly relevant to the treatment of inflammatory bowel disease. The first study pertains to the one-third of patients with ulcerative colitis who still require colectomy, primarily due to refractory disease. As the study shows, biologic agents can significantly reduce the need for colectomy. Although use of biologics in people with ulcerative colitis has increased in recent years, it is my opinion that many patients with severe disease could benefit from earlier treatment with the drugs instead of repeated courses of corticosteroids and aminosalicylates. The findings of the study strongly suggest that for moderate to severe UC, colectomy rates are lower with the more effective biologic therapies, and we shouldn’t persist with the use of nonbiologics in these sicker patients.
Trending
- 7 HLTH Announcements You Don’t Want to Miss (MedCity News)
- Practical Tips for Contracting, Part 2 (GI & Endoscopy News)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings (GRAIL)
- Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates (AJMC)
- St. Charles Health System Taps WovenX to Transform GI Access and Optimize Capacity (PR Newswire)
- United Digestive adds 5 gastroenterologists in 3 months (Becker’s GI & Endoscopy)
- Negotiated Prices for Large Insurers and Regional Differences in Employed Cardiology and GI Groups Revealed (Medscape)
- Health care in the USA: money has become the mission (The Lancet)
